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INTRODUCTION
Induced pluripotent (iPS) cells are
generated by reprogramming of somatic
cells by induced expression of the four
transcription factors Oct4, Sox2, Klf4 and
c-Myc (1–3). Similar to embryonic stem
cells (ESC), iPS cells are able to differen-
tiate into all of the different cell types
that comprise the organs of an adult
body including neuronal subpopulations
(1–6). However, individual iPS cells are
heterogeneous in respect to gene expres-
sion and epigenetic patterns (7–10).
Some iPS cell lines have a differentiation
bias toward their cell type of origin,
which seems to be linked to somatic
memory mechanism, a cell-type specific
epigenetic memory they retain following
reprogramming (7,8,11,12). A require-
ment for the use of iPS cell-derived neu-
rons for pharmacological or therapeutic
applications is an efficient and stabile
neurogenesis (13). Recent studies have
indicated a role for the activin/nodal,
BMP, Notch, Shh or Fgf pathways (6,14)
as well as several miRNAs (15) to exit
the pluripotent state and to initiate dif-
ferentiation.
Hypoxia promotes self-renewal and
proliferation of tissue-specific stem cells
and ESCs (16). In human iPS cells, hy-
poxia promotes reprogramming and en-
hances iPS cell production (17) and neu-
ronal differentiation (18). Hypoxia also is
a potent inducer of gene expression of
the hematopoietic growth factor erythro-
poietin (EPO) (19). EPO and its receptor
(EPOR) are best known for their role in
regulating erythroid proliferation and
differentiation (19) but EPO and EPOR
also are expressed in the nervous system
(20) where they exert potent cytoprotec-
tive and trophic activities (20–23). A sub-
stantial amount of effort has been de-
voted to characterize the mechanism of
the neuroregenerative actions of EPO
(24,25). For example, inhibition of apo-
ptosis and inflammation seem to mediate
EPO-induced neuroprotection after acute
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brain injuries (24,25) while the trophic
and myelination promoting effects of
EPO may be important for its ability to
counteract chronic neurodegeneration
and neuroinflammation (26–29). Direct
effects on neural stem cells also may play
a role in the neurorestorative actions of
EPO in rodent models of ischemic and
traumatic brain injury (30–33). In these in
vivo models, EPO improves injury-in-
duced neurogenesis (31–33) and stimu-
lates oligodendrogliosis (33). Accord-
ingly, deletion of EPOR in the nervous
system reduces the size of the neural
stem cell pool and impairs injury-
 induced adult neurogenesis (30,34). Hy-
poxic preconditioning of neural stem
cells induces EPO and improves neu-
ronal differentiation (35) but it is not
known whether EPO can stimulate neu-
rogenesis from pluripotent stem cells. In
this study, we examined whether EPO
and EPOR play a role in the generation
of neuronal cells from iPS cells. For this
purpose we first characterized neurogen-
esis of iPS cells (1), and studied the ef-
fects of EPO on proliferation and neuro -




For all experiments, iPS cells repro-
grammed from murine neural stem cells
by ectopic Oct4, Klf4, c-Myc and Sox2 ex-
pression, expressing lacZ from the
rosa26 locus and carrying a Oct4-GFP
transgene (1) were used. The mouse
ESC wtB1 cell line carrying a β-actin-
GFP transgene (36) was used as a posi-
tive control for pluripotent gene expres-
sion (Figure 1C). Cells were cultured on
inactivated murine embryonic fibrob-
lasts (MEF) in 60-mm plates (BD Bio-
sciences, Heidelberg, Germany) in
DMEM medium supplemented with
15% FCS, 1% nonessential amino acids,
1% penicillin/streptomycin, 1 mmol/L
sodium pyruvate, 2 mmol/L L-gluta-
mate, 10 mmol/L 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES)
(all from PAA Laboratories GmbH,
Hamburg, Germany), 0.1 mmol/L 
β-mercaptoethanol (Sigma-Aldrich,
Taufkirchen, Germany) and leukemia
inhibitory factor at 37°C/5% CO2 and
passaged every 2–3 d. Medium was
changed every second day. For passag-
ing, cells were washed once with PBS
and detached from the culture plates by
trypsin/EDTA (PAA Laboratories
GmbH) treatment for 5 min at 37°C. The
reaction was stopped after 5 min with
DMEM medium supplemented with
10% FCS and cells were collected,
washed and replated onto fresh feeders.
Neural Differentiation of iPSC Cultures
iPS cells and ESCs were differentiated
into panneural progenitor cells (pNPCs)
using a monolayer differentiation proto-
col (37) with the following modifications:
iPS cells and ESCs were passaged and
the cells were plated onto 100 mm plates
(Greiner Bio-One, Frickenhausen, Ger-
many) coated with 0.1% gelatin from
bovine skin in PBS (Sigma-Aldrich) and
incubated at 37°C to separate iPS/ES cells
and MEFs. After 45 min, iPS or ES cells
were collected from the gelatin-coated
plates, washed, counted and replated on
gelatin-coated 60 mm plates (BD Bio-
sciences) in GMEM medium (Life Tech-
nologies GmbH, Darmstadt, Germany)
supplemented with 10% FCS, 1%
penicillin/ streptomycin, 2 mmol/L 
L-glutamate, 10 mmol/L HEPES (all from
PAA Laboratories GmbH), 0.1 mmol/L
β-mercaptoethanol (Sigma-Aldrich) and
leukemia inhibitory factor with a density
of 400,000 cells/plate for iPS cells and
200,000 cells/plate for ESCs. After 24 h,
medium was replaced with N2B27 me-
dium (37) and cells were differentiated
for 5 d at 37°C/5% CO2. N2B27 medium
was changed every second day.
Expansion of pNPCs
pNPCs were washed once with PBS
and detached from the culture plates
with trypsin/EDTA (PAA Laboratories
GmbH) for 5 min at 37°C , washed and
plated in 25-cm2 suspension culture
flasks (Greiner Bio-One) with a density
of 1,000,000–1,500,000 cells per flask and
cultured in 7 mL pNPC medium com-
posed of DMEM/F12 medium supple-
mented with 2 mmol/L L-glutamate,
15 mmol/L HEPES, 0.22% sodium bicar-
bonate, 2% B27 without vitamin A (all
from Life Technologies GmbH), 1% peni-
cillin/streptomycin (PAA Laboratories
GmbH), 0.6 g glucose (Sigma-Aldrich),
20 ng/mL hEGF and 20 ng/mL bFGF2
(both from Peprotech, Hamburg, Ger-
many). pNPCs were cultured at 37°C
under 5% CO2/95% air and 90% humid-
ity for 5 to 6 d. Medium was replaced
every third day.
pNPC-generated spheres were pas-
saged on d 5 or 6 according to the follow-
ing protocol: pNPC-spheres were first in-
cubated in AccuMax (PAA Laboratories
GmbH) for 5 min at 37°C and mechani-
cally triturated into single cells with a fire-
polished Pasteur pipette. pNPCs were re-
plated in 7 mL pNPC medium density of
1,000,000–1,500,000 cells per flask.
Analysis of Oct4-GFP Fluorescence
GFP fluorescence was analyzed with
an Olympus IX70 fluorescence micro-
scope (Olympus, Münster, Germany)
and images were taken using the Analy-
SIS software (Soft Imaging System
GmbH, Münster, Germany). In addition,
the loss of GFP fluorescence during dif-
ferentiation was analyzed by flow cy-
tometry. Cells at d 0 and 5 of differentia-
tion were detached from the culture
plates as described, collected, washed,
resuspended in PBS (Sigma-Aldrich) and
analyzed using a BD FACSCanto and
FACSDiva software (BD Biosciences).
FACS data was analyzed using the soft-
ware Weasel.
Differentiation of pNPCs
Secondary pNPC-spheres were disso-
ciated into single cells and plated on
poly-D-lysine (PDL; Sigma-Aldrich)
coated glass coverslips (Paul Marienfeld
GmbH & Co KG, Lauda-Königshofen,
Germany) in 24-well cell culture plates
(Greiner Bio-One) at a density of 25,000
cells/well in B27 medium consisting of
neurobasal medium supplemented with
2% B27 (both from Life Technologies
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Figure 1. Characterization of in vitro neurogenesis of iPS cells and neural differentiation of iPS pNPCs. (A) Time scale diagram for neural
differentiation of iPS cells and pNPC expansion as neurospheres. Left panel shows typical alkaline phosphatase positive iPS cell colonies
(red). The rest of the panels depict overlays of phase contrast images and the GFP signal of Oct-4-driven GFP. iPS cells were positive for
GFP; pNPCs, neurospheres and expanded pNPCs were negative for GFP. (B) FACS quantification of the Oct-4-GFP positive cells (P1) at d
0 and d 5 of differentiation for clonal line 1 (C1) and 2 (C2). Data are represented as mean ± SD, n = 3. (C) Expression analysis of different
pluripotency and neural genes by RT-PCR in iPS cells and pNPCs. Mouse embryonic stem cell line (ESC wtB1), wtB1-derived pNPCs, neural
stem cells (mNSC) and mouse embryonic fibroblasts (MEF) were used as controls. (D) Percentage of cells from C1 and C2 expressing
markers for neurons (MAP-2), oligodendrocytes (PDGFR) and astrocytes (GFAP) at d 10 of differentiation. Data is represented as mean ±
SD, n = 3. (E) Representative images of marker expression during pNPC differentiation. At d 0 of differentiation cells expressed the neural
stem cell marker nestin and the neuronal progenitor marker Pax6. After 10 d in culture pNPCs expressed the neuronal markers MAP-2 and
TAU, the astrocytic marker GFAP and the oligodendrocytic marker PDGFR. Staining for the oligodendrocyte marker O4 became visible
after 14 d of differentiation. After 22 d, cells expressed the presynaptic marker synapsin, the postsynaptic marker homer1 and myelin
basic protein, a marker for mature oligodendrocytes. (F) Immunochemical labeling of active synapses. Fluorescent picture showing stain-
ing for synapsin (green), and synaptotagmin I (red) and the mask for analyzing the frequency of colocalized dots (yellow, arrowhead).
Graph shows the quantification of the mean percentage of double stained dots. Data represent mean ± SD, n = 3. (G) Electrophysiologi-
cal characterization of pNPCs at d 13/14. I/V curves of VC-stimulation in pNPC C1 neuronlike cells before and after treatment with ttx
(tetrodotoxin, sodium channel blocker) or TEA (tetraethylamonium, potassium channel blocker). Stimulation potential [mV] is plotted
against the maximum measured inward or outward current (current was normalized to cell size [pA/pF], data represent mean ± SD; n =
6, *p < 0.05, **p < 0.01 (paired t test for normal and Wilcoxon test for not normal distributed samples). A representative trace of mem-
brane potential responding to step depolarization by current injection (depolarizations: black lines; hyperpolarizations: gray lines) and a
representative trace of whole cell currents in voltage clamp mode responding to step depolarization by current injection. Current injec-
tions (–50 pA, +10 pA) into pNPC-derived neurons in current clamp (CC)-mode. Stimulation via stepwise increase of membrane potential
(–80 mV to +55 mV, step size 15 mV) in VC-mode. Scale bars (A): first and fourth subpanels from left, 100 μm; second, third and fifth sub-
panels from left, 50 μm; (E): top subpanels and second through fourth bottom subpanels, 25 μm; first and fifth bottom subpanels, 10 μm. 
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GmbH), 1% penicillin/ streptomycin and
2 mmol/L L-glutamine (both from PAA
Laboratories GmbH). pNPCs were cul-
tured at 37°C under 5% CO2/95% air
and 90% humidity and medium was re-
placed every fourth day.
RT PCR
Total RNA was isolated using TRIzol
(Life Technologies GmbH) according to
the manufacturer’s instructions. 1 μg of
total RNA was treated with 1 U DNAseI
(Fermentas, St. Leon-Rot, Germany) for
40 min at 37°C to remove remaining
DNA. mRNA was transcribed into cDNA
with the Maxima Reverse transcriptase
(Fermentas) at 50°C for 60 min. cDNA
fragments from the genes of interest
were amplified by standard PCR using
gene-specific primers (Supplementary
Table S1). Mouse β-actin primers were
used as internal standard.
Immunocytochemistry
pNPCs were fixed for 20 min in 4%
PFA (Sigma-Aldrich) after 0, 10, 14 or 
22 d in differentiation, permeabilized
and blocked in 0.2% Triton X-100
(Roche, Penzberg, Germany) with 10%
normal horse serum (NHS) in phos-
phate buffered saline (PBS) (Dianova,
Hamburg, Germany) for 30 min. Cells
were then incubated with primary anti-
bodies (Supplementary Table S2)
against neural cell markers in 1% NHS
at 4°C overnight, followed by incuba-
tion with a secondary antibody (Sup-
plementary Table S2) in 1% NHS for 
1 h. Cells were mounted in Mowiol
with  4′,6-diamidino-2-phenylindole
(DAPI) for nuclear counter staining.
Cells were photographed with a Leica
LSM TCS SP5 confocal microscope
(Leica, Wetzlar, Germany). Images were
processed using the ImageJ software
(MBF ImageJ for Microscopy) (38) and
CorelDRAW Graphics Suite X5.
Cell Counting
pNPCs differentiated for 10 d were
fixed and stained for microtubule-
 associated protein 2 (MAP-2), glial fib-
rillary acidic protein (GFAP) or platelet-
derived growth factor receptor α
4 0 2 |  O F F E N E T  A L .  |  M O L  M E D  1 9 : 3 9 9 - 4 0 8 ,  2 0 1 3
E P O  A N D  N E U R O G E N E S I S  O F  i P S  C E L L S
Figure 1. Continued.
(PDGFRα) as described above. For each
marker, photos from three coverslips
(five randomly chosen fields/coverslip)
were taken using an Axiophot2 fluores-
cence microscope (Zeiss, Jena, Germany)
with a SPOT Insight camera (Visitron
Systems, Puchheim, Germany). From
each image taken the number of living
and dead (DAPI) as well as MAP-2,
GFAP or PDGFR positive cells were
counted. The experiment was replicated
twice.
Synaptic Vesicle Recycling
pNPCs differentiated for 22 d, were in-
cubated with a rabbit anti-synaptotagmin I
antibody (1:00, Synaptic Systems, Göt-
tingen, Germany) against the luminal
domain of the protein in high potassium
Krebs-Ringer-HEPES buffer (KRH) 
(55 mmol/L KCl, 85 mmol/L NaCl, 
10 mmol/L HEPES, pH 7.4, 10 mmol/L
glucose, 2.6 mmol/L CaCl2 and 
1.3 mmol/L MgCl2) for 1 min at 37°C.
The antibody solution was removed and
cells were washed thrice in KHR buffer 
(5 mmol/L KCl, 140 mmol/L NaCl, 
10 mmol/L HEPES, pH 7.4, 10 mmol/L
glucose, 2.6 mmol/L CaCl2 and
1.3 mmol/L MgCl2) for 5 min. Cells
were fixed and incubated with a mouse-
anti-synapsin I antibody (1:1,000;
Synaptic Systems) followed by an incu-
bation with a goat anti-mouse-DL488
and goat anti- rabbit-Cy3 antibody
(1:1,000, both from Dianova, Hamburg,
Germany) as described above. Photo-
graphic images from three coverslips
(three randomly chosen fields/ cover-
slip) were taken using an Axiophot2 flu-
orescence microscope with a SPOT In-
sight camera. Pictures were processed in
ImageJ (38) using the following proto-
col: images were smoothed using a
gaussian filter with σ = 2, Laplace fil-
tered and thresholded to isolate small
maxima in fluorescence intensity corre-
sponding to synaptic buttons. To in-
crease the signal-to-noise ratio a particle
filter with a threshold of 16 pixels was
applied. The total number of synapsin I
positive buttons and the number of but-
tons colocalizing with synaptotagmin I
staining were counted. The experiment
was replicated twice.
Whole Cell Patch-Clamp Analysis
Cells were transferred into a record-
ing chamber and continuously super-
fused with extracellular solution con-
taining 125 mmol/L NaCl, 25 mmol/L
NaHCO3, 25 mmol/L glucose, 
2.5 mmol/L KCl, 1.25 mmol/L NaH2PO4,
2 mmol/L CaCl2, 2 mmol/L MgCl2
purged by 95% CO2/5% O2. The ion
channel antagonists tetraethylammo-
nium chloride (TEA) or tetrodotoxin
(ttx) (both from Sigma-Aldrich) were
added to the extracellular solution with
a concentration of 30 mmol/L and 
1 μmol/L, respectively. All experiments
were performed at room temperature
using an EPC 10 double patch clamp
amplifier and pulse software (HEKA,
Lambrecht, Germany). Electrodes were
pulled from thick-walled borosilicate
glass (Warner Instruments, Hamden,
CT, USA) and filled with intracellular
solution (120 mmol/L K-gluconate, 
32 mmol/L KCl, 10 mmol/L HEPES,
4 mmol/L NaCl, 0.5 mmol/L EGTA,
4 mmol/L MgATP, 0.4 mmol/L 
Na2-GTP, pH 7.2, 290-300 mOsml
–1) 
and had a resistance between 4 and 
6 MΩ. Cells were held in whole-cell
configuration at –70 mV and were dis-
carded if the series resistance was
higher than 25 MΩ at the beginning of
the measurements.
EPOR Activity Assay
Activation of the EPOR-associated
signaling was investigated by Western
blot analysis of the phosphorylation of
ERK 1/2. Secondary pNPC-spheres
were dissociated into single cells as de-
scribed above and seeded into 25-cm2
suspension culture flasks with a density
of 1,500,000 cells. After 24 h, 1 U/mL
human recombinant EPO (epoetin beta,
NeoRecormon, Roche, Welwyn Garden
City, UK) or PBS was added to the sus-
pension culture and total cell protein
was extracted 5 min after treatment
using PhosphoSafe (Merck, Darmstadt,
Germany) according to the manufac-
turer’s instructions. Protein concentra-
tion was measured with the BCA Pro-
tein Assay (Thermo Fisher Scientific,
Schwerte, Germany) and stored after-
ward at –80°C. Five volumes of protein
solution were mixed with 1 volume of
Laemmli buffer (250 mmol/L Tris HCl,
pH 8.3, 8% SDS, 40% glycerol, 20% 
2-mercaptoethanol, 0.04% pyronin Y)
and boiled for 5 min at 95˚C. Ten to fif-
teen μg protein was run on 15% poly-
acrylamide gels (Roth, Karlruhe, Ger-
many) for 2 h at 150 V and transferred
to a nitrocellulose membrane for 1 h at
400 mA using a miniVE electrophoresis
and electro transfer unit (Amersham
Bioscience/GE Healthcare, Munich,
Germany). After blocking with 5% milk
powder in Tween20-Tris-buffered saline
(TTBS), at room temperature for 1 h, the
membranes were incubated with pri-
mary antibodies for mouse anti-pMAPK
(1:2,000, Sigma-Aldrich) or rabbit anti-
MAPK (1:5,000, Sigma-Aldrich). Im-
munoreactive bands were visualized
using a secondary anti-mouse (1:5,000)
or anti-rabbit (1:15,000) antibody cou-
pled to horseradish peroxidase (both
from Sigma-Aldrich) by enhanced
chemiluminescence (ECL Prime Western
blotting detection kit, Amersham Bio-
science/GE Healthcare). Densitometric
analysis of protein bands was per-
formed using the ImageJ software.
Cell Survival Assay
For the pNPC survival assay, second-
ary spheres were dissociated into single
cells and plated at a density of 50,000
cells on PDL coated glass coverslips in
24-well cell culture plates. pNPCs were
cultured in B27 medium with 0.1, 1 or
10 U/mL EPO or PBS. After 24 h or 48 h
MTT cell survival assay was performed
according to the following protocol:
pNPCs were incubated in B27 medium
supplemented with 30 mmol/L thiazolyl-
blue- tetrazolium-bromide (MTT; Sigma-
Aldrich) for 2 h at 37°C/5% CO2. Cells
were washes with PBS and treated for
5 min with cell lysis buffer (50% N,N-
 dimethylformamide, 20% sodium dode-
cylsulfat, pH 4.7). The absorption of the
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formazan product that is produced by
metabolization of the MTT reagent was
measured at 570 nm. Cell vitality of the
EPO treated cells was calculated from
the absorption as follows: 
Cell vitality [%] = 
Mean Abs570nm EPO treatment/
Mean Abs Abs570nm control treatment 
× 100. 
Control was set as 100%. Four indepen-
dent experiments in six replicates of
every treatment group were performed
for each clone.
pNPC Dilution Assay
Secondary pNPC-spheres were dissoci-
ated into single cells and seeded with a
density of 1, 10, 25, 50, 100, 250, 500, 750,
1000, 1500 or 2500 cells per well into 96-
well suspension culture plates (Greiner
Bio-One) containing 200 μL of pNPC me-
dium. Cells were treated immediately ei-
ther with 0.3 or 1 U/mL EPO or placebo
and cultured for 7 d without changing
the medium. At d 7, all spheres/well
were photographed using an Olympus
IX70 inverse microscope and the Analy-
SIS software and counted. Sphere diame-
ter was measured using ImageJ (38).
Analysis was performed blinded. Four
independent experiments were per-
formed for each clone. For each experi-
ment, three replicates of every treatment
group were analyzed.
pNPC Proliferation Assay
Single pNPCs derived from secondary
spheres were labeled with 0.2 μmol/L
carboxyfluorescein-succinimidyl-ester
(CFSE) (Sigma-Aldrich) in PBS (1,000,000
cells/mL) for 10 min at 37°C, mixture of
ice-cold PBS and pNPC medium without
hEGF and bFGF2 was added and cells
were incubated for 5 min on ice followed
by three washing steps in PBS. Immedi-
ately after washing an aliquot of CFSE-
labeled and unlabeled cells were ana-
lyzed using a BD FACSCanto and
FACSDiva software.
Labeled cells were seeded into 25-cm2
suspension culture flasks with a density
of 1,000,000 cells/flask and grown in
pNPC medium supplemented with 
1 U/mL EPO or placebo. After 48 h,
newly formed pNPC-spheres were disso-
ciated into single cells and analyzed by
flow cytometry. FACS data was evalu-
ated using Weasel software. For each
clone, four independent experiment were
 performed.
In a separate set of experiments, CFSE-
labeled cells were incubated in 5 mL
pNPC medium without growth factors
containing either DMSO, 10 μmol/L
LY294002 or 10 μmol/L U0126. After 
20 min, placebo or 1 U/mL EPO was
added and cells were incubated for an
additional hour. Afterward, cells were
washed twice in PBS and seeded into 
25-cm2 suspension culture flasks in 5 mL
pNPC medium and incubated at 37°C
under 5% CO2/ 95% air and 90% humid-
ity. After 48 h, CFSE fluorescence was an-
alyzed by flow cytometry as described
above. For each clone, three to four inde-
pendent experiments were performed.
Cell Cycle Analysis
pNPCs were derived from secondary
spheres as described above. One million
cells in 5 mL pNPC medium were incu-
bated in the presence of 5 μg/mL aphidi-
colin (SERVA Electrophoresis GmbH,
Heidelberg, Germany) for 14 h. After 14 h,
cells were washed twice in PBS and incu-
bated in 5 mL pNPC medium supple-
mented with 1 U/mL EPO or placebo for
10 and 24 h. Afterward, cells were washed
twice in PBS and fixed in 3% PFA for 
15 min. After fixation cells were washed
once in PBS and stained in 500 μL PBS
containing 50 μg/mL propidium iodide
(PI, Sigma-Aldrich), 0.1 mg/mL RNAseA
(Fermentas) and 0.05% Triton X-100 for
40 min at 37°C. PI labeled cells were ana-
lyzed using a FACSCanto and FACSDiva
software. FACS data was evaluated
using Weasel software. For each clone,
three to four independent experiments
were performed.
Neuronal Differentiation Assay
Secondary spheres were dissociated
into single cells and plated on PDL
coated glass coverslips in 24-well cell cul-
ture plates with a density of 12,500
cells/coverslip and grown in B27 me-
dium with 3 U/mL EPO or placebo. After
2, 4 or 6 d, cells were fixed and stained
with a mouse-anti-β-III-tubulin primary
(1:500, Sigma-Aldrich) and an anti-
mouse-Cy3 (1:1000, Dianova) secondary
antibody, and counterstained with DAPI.
Pictures from two coverslips (eight ran-
domly chosen fields/coverslip) were
taken using an Axiophot2 fluorescence
microscope with a SPOT Insight camera.
The number of living (DAPI) and β-III-
tubulin (TuJ1)-positive cells was counted.
In addition, the length of each process of
TuJ1-positive cells was measured using
the NeuronJ plugin for the ImageJ soft-
ware (21). Cells with processes shorter
than the cell soma’s diameter were ex-
cluded from further analysis. Measure-
ments and data analysis was performed
blinded.
Statistical Analysis
Data are expressed as mean ± SD for
indicated number of repetitions (n). Data
were tested for normal distribution using
a graphical approach (quantile-quantile
Plot) and the Shapiro–Wilk test. Group
differences with normal distribution
were analyzed by Student t test and the
Wilcoxon test was used for not normally
distributed datasets. Data plotting and
statistical analysis were done using Mi-
crosoft Excel and R (39). Differences were
considered significant at p < 0.05.
All supplementary materials are available
online at www.molmed.org.
RESULTS
Neurogenesis of iPS Cells
To assess the potential of iPS cells for in
vitro neurogenesis, we first induced their
differentiation into pNPCs by culturing
the cells for 5 d followed by pNPC expan-
sion as neurospheres for additional 10 to
12 d (Figure 1A). During neural differenti-
ation the iPS cells lost the expression of an
Oct-4-driven GFP- transgene within 5 d
(Figures 1A,1B). At this stage, the pNPCs
were negative for the pluripotency genes
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Nanog, Rex1 and Fgf4 (Figure 1C) and
started to express neural stem cell markers
nestin and musashi (see Figure 1C). As ex-
pected, pNPCs but not iPS cells expressed
genes involved in forebrain (Emx2, Dlx5)
or midbrain/hindbrain development
(Nkx6.1, Dlx2 and Hoxa2) (40–42).
Neural Differentiation and Maturation
of iPS pNPCs
When the cells were cultured under
neuronal differentiation conditions for
10 d pNPCs became positive for neuronal
and glial markers (Figure 1D,1E). Count-
ing of frequencies of neural cell types after
10 d of differentiation (see Figure 1D) re-
vealed that 33% (clonal line C1) and 43%
(clonal line C2) of all cells expressed the
neuron-specific protein, microtubule-
 associated-protein 2 (MAP2), whereas 25%
(C1) and 21% (C2) expressed the oligoden-
drocyte marker platelet-derived growth
factor receptor (PDGFR). Less than 1% of
all cells were positive for the astrocyte spe-
cific protein, glial fibrillary acidic protein
(GFAP) (see Figure 1D). Figure 1E shows
representative images of cells at various
stages of differentiation. Immediately after
plating iPS pNPCs were positive for the
neural precursor marker nestin. Some of
them also expressed the neuronal progeni-
tor marker Pax6 (see Figure 1E). In 10 d
old cultures, the expression of the neu-
ronal markers MAP2 and TAU as well as
the oligodendrocyte marker PDGFR were
prominent and the astrocyte marker GFAP
was detectable in few cells. Staining for
the oligodendrocyte marker O4 (see Fig-
ure 1E) and the presynaptic marker
synapsin became visible after 14 d of dif-
ferentiation. After 22 d in culture, synapsin
expression was pronounced and cells ex-
pressed the postsynaptic marker homer1
(see Figure 1E). Expression of myelin basic
protein (MBP), a marker for mature oligo-
dendrocytes became also detectable after
22 d in culture (see Figure 1E). At this
stage of in vitro maturation, roughly one
fourth (23% to 24%) of the neuronlike cells
showed the presence of active presynaptic
terminals after induction of presynaptic
vesicle fusion by a brief exposure to
55 mmol/L KCl (Figure 1F).
To further confirm that the iPS-derived
neuronlike cells develop functional neu-
ronal properties, we performed whole cell
patch clamp recordings at d 13 and 14 of
differentiation. The cells were stimulated
in current clamp (CC) mode with depolar-
izing current injections (–50 pA to +130 pA,
step size 20 pA) over a time period of
500 ms. In 11 out of 16 (C1) and 10 out of
20 (C2) recorded cells current injection
elicited action potentials, multiple action
potentials could be elicited (Figure 1G).
The average resting membrane potential
for the recorded cells was –44.81 ± 9.01 mV
(C1) and –48.38 ± 13.38 mV (C2), respec-
tively. In voltage clamp (VC) mode we
stepwise depolarized the cells (–80 mV to
+55 mV, step size 15 mV) to induce action
potentials and measured the correspon-
ding inward and outward currents. Neu-
ronlike cells from both clonal lines showed
a similar pattern of maximum inward and
outward currents plotted against the volt-
age stimulus, however C2 showed a ten-
dency for lower outward currents com-
pared with clone 1 (Figure 1G and not
shown). As expected, treatment of cells
with the Na+-channel inhibitor tetrodotoxin
(ttx) or the K+-channel inhibitor tetraethy-
lammonium (TEA) completely abolished
inward (Na+) and reduced outward (K+)
currents (see Figure 1G).
Effect of EPO on iPS pNPCs
We first confirmed that pNPCs from
both iPS clones express EPOR mRNA
and functional EPOR by monitoring the
EPO-induced activation of MAPK signal-
ing (Figure 2A). When the cells were cul-
tured for 24 h under different concentra-
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Figure 2. Effect of EPO on iPS pNPCs. (A) pNPCs express EPOR mRNA and functional EPOR:
EPO treatment leads to an increase in ERK1,2 (MAPK) phosphorylation (n = 6, C1; n = 4,
C2). (B) Effect of EPO treatment on cell survival after 24 h and 48 h (n = 4 in each group).
(C) Effect of EPO on pNPC proliferation (n = 4 in each group). The percentage of fast pro-
liferating cells (cells gated with low CFSE signal in inset) is decreased in both clonal lines
after EPO treatment. (D) Effect of EPO on sphere formation under different seeding con-
centration (n = 4 in each group). (E) The number of TuJ1-positive neurons in cultures
treated with placebo or EPO (1 U/mL) (n = 4 in each group). The average number of liv-
ing cells per field was 19 ± 7 (placebo) and 29 ± 13 (EPO) for d 2, 19 ± 7 (placebo) and
22 ± 11 (EPO) for d 4 and 17 ± 8 (placebo) and 16 ± 5 (EPO) for d 6, respectively. Data
represent mean ± SD for the indicated number of samples, *p < 0.05, **p < 0.01 versus pla-
cebo, #p < 0.05 versus EPO 0.1 U/mL (B) or versus EPO 0.3 U/mL (D); t test for normal and
Wilcoxon test for not normal distributed samples.
tions of EPO, cell survival in C2 was im-
proved by EPO concentrations of
1 U/mL and 10 U/mL (Figure 2B). A ten-
dency for a better cell survival after EPO
also was observed in C1 (see Figure 2B).
A similar pattern of cell survival also
was seen in cells cultured for 48 h (see
Figure 2B). When the effect of EPO on
cell proliferation was tested by CFSE cell
proliferation assay, EPO (1 U/mL) re-
duced cell proliferation in both cell
clones (Figure 2C). Since binding of EPO
to EPOR activates ERK1/2 and Akt-1 sig-
naling in neurons (21–23), we tested
whether pretreatment with inhibitors of
these pathways can modify the effect of
EPO on pNPC proliferation. Treatment
with the PI3K-inhibitor LY294002
(10 μmol/L) or the MAPK inhibitor
U0176 (10 μmol/L) failed to influence
the antiproliferative effect of EPO consis-
tently (Figures 3A–B). Cell cycle analysis
of pNPCs showed no changes in cell
cycle progression after EPO treatment
(Figure 3C).
To analyze the effect of EPO on neu-
rosphere formation, pNPCs were plated
with different densities from 1 up to
2,500 cells/well and were allowed to
form spheres for 7 d in the presence of
0.3 or 1 U/mL EPO or placebo. After 7 d,
EPO suppressed sphere formation in a
dose dependent manner (Figure 2D). For
assessment of the effect of EPO on neu-
ronal differentiation, pNPCs were cul-
tured under culture conditions favoring
differentiation in the presence or absence
of 3 U/mL EPO. EPO treatment more
than doubled the number of TuJ1-
 positive neurons at d 4 and 6 (Figure 2F).
Together this indicates that EPO facili-
tated neurodifferentiation of iPS-derived
pNPCs.
DISCUSSION
Efficient generation of neural cell types
from pluripotent embryonic or iPS cells
have been the subject of intensive re-
search (6,14,43–46), but factors that lead
to a robust formation of pNPCs from
pluripotent stem cells and/or their dif-
ferentiation into neural subtypes still
need to be identified. In the present
study we first show that the hematopoi-
etic growth factor EPO directs iPS pNPC
neurogenesis into neuronal fate by in-
hibiting proliferation and promoting
neuronal differentiation.
We first confirmed the potential of iPS
cells to generate proliferating pNPCs,
which further differentiated into mature
neurons and oligodendrocytes. iPS cell-
derived neuronlike cells showed the
ability to generate action potentials, pos-
sessed membrane characteristics similar
to newly formed neurons (47,48) and
were capable of forming active presy-
naptic terminals. In this regard our find-
ings are in accordance with several other
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Figure 3. iPS pNPC proliferation and cell cycle analysis. The PI3K inhibitor LY294002 (A) or
the MAPK-inhibitor U-0126 (B) have no consistent effect on EPO-induced reduction of
pNPC proliferation (percentage of CFSElow cells after 48 h). (C) Cell cycle analysis of pNPC
proliferation. EPO treatment did not change the percentage of cells in G1, S or G2-phase
after 10 h of treatment in either clonal lines. Data in all panels represent mean ± SD, n = 3
(C1), n = 4 (C2); *p < 0.05, **p < 0.01 (paired t test for normal and Wilcoxon test for not
normal distributed samples).
studies that showed the ability of
murine iPS cell lines to generate differ-
ent neural subtypes, including func-
tional neurons (6,45,49,50). The iPS cell-
derived progenitors in our study
produced mainly neurons and oligoden-
drocytes. In contrast to earlier studies
showing the generation of 10% astro-
cytes from murine iPSCs (6,51), we de-
tected less than 1% astrocytes. These dif-
ferences might be explained by
differences in the reprogramming pro-
cess and the origin of the somatic cell
used for iPS cell generation, as our cells
might have a differentiation bias toward
neurons due to their type of origin
(1,5,43,52,53). Culture conditions such as
the concentration of EGF and bFGF2 in
culture media also may have influenced
the neural cell fates (54,55).
In the second part of the study, we an-
alyzed the potential of EPO to modulate
neurogenesis in two clones of iPS pNPCs
which expressed functional EPOR. We
observed that EPO increased cell viabil-
ity of pNPCs. This is not surprising
given the fact that the antiapoptotic and
cytoprotective effects of EPO have been
reported in several in vivo and in vitro ex-
perimental settings (25). An alternative
explanation for the increase in viable
cells after EPO treatment would be a
stimulation of cell proliferation. How-
ever, we found that EPO had an in-
hibitory effect on cell proliferation. Treat-
ment with EPO thus seems to improve
the maintenance of a homogenous and
stabile neural cell type. Furthermore, the
competence of pNPCs to form spheres
was drastically reduced by EPO. In
agreement with our findings, Shingo and
colleagues described an inhibitory effect
of EPO on neurosphere formation and
growth from neural stem cells isolated
from fetal rat brain (35). Others have re-
ported stimulation of proliferation of
adult neural stem cells in response to
EPO treatment (34,56–58). These oppos-
ing results may be related to different
cell culture types and to the use of higher
EPO concentrations.
MAPK and PI3/AKT signaling have
been shown to support neurosphere for-
mation and/or growth in neural stem
cells (59). These signaling pathways also
have been shown to be activated by EPO
in neurons (21–23,28,57,60). Even if iPS
cell-derived pNPCs expressed EPOR
mRNA and functional EPOR-associated
intracellular signaling pathways, neither
inhibition of MAPK nor PI3K/AKT
counteracted the effect of EPO on iPS
pNPC proliferation. Therefore, relevant
pathways mediating the EPO-induced
inhibition of cell proliferation remain to
be determined.
Finally, we show that in differentiating
cultures of iPS pNPCs treatment with
EPO led to increased numbers of TuJ1-
positive neurons. These findings agree
with previous reports on EPO-induced
improvements in neuronal differentia-
tion of fetal and adult neural stem cells
(35,61).
CONCLUSION
We generated panneural progenitor
cells (pNPCs) from mouse iPS cells and
investigated the effect of the neu-
rotrophic growth factor erythropoietin
on their survival, proliferation and neu-
rodifferentiation. We show that EPO in-
hibits self-renewal and promotes neuro-
genesis of these cells. This novel effect of
EPO may bear clinical relevance, as EPO
might be used to improve the production
and maintenance of a homogeneous and
stabile neural stem cell population from
human iPS cells.
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